PFM Health Sciences’s Blueprint Medicines BPMC Stock Holding History

PFM Health Sciences’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-336,800	Closed	-$27M	–	65
2019 Q4	$27M	Buy	+336,800	New	+$25.2M	1.29%	32

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

PFM Health Sciences's BPMC Position: Q3 2025 in Review

PFM Health Sciences sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 48,444 shares — an estimated $6.21M sold.

PFM Health Sciences first reported a position in BPMC in Q2 2015 and held it in 21 quarters. The position peaked at $113M in Q3 2017. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

PFM Health Sciences reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
PFM Health Sciences sold 48,444 Blueprint Medicines shares in Q3 2025, an estimated $6.21M.
PFM Health Sciences first reported a position in Blueprint Medicines in Q2 2015 and held it in 21 quarters.
PFM Health Sciences's Blueprint Medicines position peaked at $113M in Q3 2017.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on PFM Health Sciences's 13F filing for Q3 2025, filed 14 Nov 2025.